Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to ...

GE HealthCare trimmed its financial forecasts for the remainder of the year in the face of U.S. | GE HealthCare said that ...

An investor is ratcheting up the pressure on Acelyrin to pull out of a planned merger with Alumis, setting out its case for ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Parkinson’s disease has always been a complex puzzle, for patients and researchers alike, with contributing factors ranging ...

Pink slips have followed the green light at Entrada Therapeutics. | Pink slips have followed the green light at Entrada ...

Ono Pharma’s U.S. arm is laying off 83 staffers at its site in Cambridge, Massachusetts. | The affected Cambridge site is Ono ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...